Related Experiment Video

Updated: Aug 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Acute hepatitis C]

Wiesław Kryczka1

  • 1Oddziałł Obserwacyjno-Zakaźny Wojewódzkiego Szpitala Zespolonego w Kielcach,

Przeglad Epidemiologiczny
|November 24, 2004
PubMed

Insights

Early antiviral treatment for acute hepatitis C (AHC) in seropositive, non-icteric patients significantly improves outcomes. Pegylated interferon for 24 weeks is recommended, with combination therapy for non-responders.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Acute Hepatitis C (AHC) can lead to chronic infection.
  • Understanding factors influencing HCV chronicity is crucial.
  • Assessing early antiviral therapy efficacy in AHC is important.

Purpose of the Study:

  • To evaluate the natural course of AHC and identify factors associated with chronicity.
  • To assess the effectiveness of antiviral therapy initiated during the acute phase of Hepatitis C Virus (HCV) infection.

Main Methods:

  • Seventy-seven patients with AHC were analyzed.
  • Sixty-four patients were untreated, while thirteen received interferon-based therapy.
  • Therapies included interferon monotherapy, Rebetron, and PEG-Intron, with varying durations.

Main Results:

  • 64.1% of untreated patients developed chronic hepatitis.
  • Age over 40, non-icteric presentation, and medical procedures were linked to chronicity.
  • Ten of thirteen treated patients achieved sustained response; combination therapy was effective for breakthrough cases.

Conclusions:

  • Early treatment of seropositive, non-icteric AHC patients is recommended.
  • Pegylated interferon for 24 weeks appears to be the optimal choice.
  • Combination therapy with PEG and ribavirin is beneficial for non-responders, highlighting the need for earlier AHC diagnosis.
Abstract

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...